Immunocore Holdings plc (IMCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMCR POWR Grades
- IMCR scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.93% of US stocks.
- The strongest trend for IMCR is in Stability, which has been heading down over the past 179 days.
- IMCR ranks lowest in Momentum; there it ranks in the 4th percentile.
IMCR Stock Summary
- IMCR's went public 1.82 years ago, making it older than merely 7.75% of listed US stocks we're tracking.
- With a price/sales ratio of 23.2, IMMUNOCORE HOLDINGS PLC has a higher such ratio than 94.73% of stocks in our set.
- Revenue growth over the past 12 months for IMMUNOCORE HOLDINGS PLC comes in at 233.9%, a number that bests 96.33% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to IMMUNOCORE HOLDINGS PLC, a group of peers worth examining would be WATT, ATOM, CRNC, AIP, and SDGR.
- Visit IMCR's SEC page to see the company's official filings. To visit the company's web site, go to www.immunocore.com.
IMCR Stock Price Chart Interactive Chart >
IMCR Price/Volume Stats
| Current price | $60.47 | 52-week high | $69.06 |
| Prev. close | $58.95 | 52-week low | $18.43 |
| Day low | $59.00 | Volume | 324,100 |
| Day high | $61.20 | Avg. volume | 247,794 |
| 50-day MA | $53.03 | Dividend yield | N/A |
| 200-day MA | $40.78 | Market Cap | 2.66B |
Immunocore Holdings plc (IMCR) Company Bio
Immunocore Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune diseases. Immunocore Holdings serves customers in the United Kingdom and the United States.
Latest IMCR News From Around the Web
Below are the latest news stories about IMMUNOCORE HOLDINGS PLC that investors may wish to consider to help them evaluate IMCR as an investment opportunity.
Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be SustainableImmunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene TherapyuniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B. |
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track DesignationPalisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery. |
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Immunocore to present at the 5th Annual Evercore ISI HealthCONx ConferenceImmunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat |
IMCR Price Returns
| 1-mo | 5.83% |
| 3-mo | 16.51% |
| 6-mo | 84.92% |
| 1-year | 68.02% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 76.61% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...